Study to Compare the Efficacy and Safety of Passive Immunization With TNM002 Injection and Human Tetanus Immunoglobulin as Prophylaxis Against Tetanus

Condition:   Tetanus Interventions:   Drug: TNM002;   Drug: Human tetanus immunoglobulin (HTIG) Sponsor:   Trinomab Biotech Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials